Armen Goenjian
Psychiatry · Long Beach, CANPI 1588632855
Payments from drug & device makers
Across 756 payments — averaging $6995.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- H. Lundbeck A S$1.5M
- Boehringer Ingelheim$669K
- Biogen$517K
- Teva Pharmaceuticals USA, Inc.$492K
- Sunovion Pharmaceuticals Inc.$352K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$324K
- plus $1.5M from 15 others
What the payments were for
- Food & beverage$108100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| H. Lundbeck A S | 65 | $1,464,842 |
| Boehringer Ingelheim | 16 | $669,125 |
| Biogen | 4 | $516,890 |
| Teva Pharmaceuticals USA, Inc. | 102 | $491,700 |
| Sunovion Pharmaceuticals Inc. | 110 | $352,385 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 13 | $324,147 |
| AbbVie | 66 | $322,364 |
| Supernus Pharmaceuticals, Inc. | 74 | $287,294 |
| Neurocrine Biosciences, Inc. | 52 | $189,361 |
| Acadia Pharmaceuticals Inc | 87 | $177,774 |
| Hoffmann-la Roche Limited | 27 | $127,844 |
| Tolmar, Inc. | 11 | $100,681 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $91,634 |
| Alkermes, Inc. | 39 | $90,517 |
| Eisai Inc. | 24 | $43,478 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 31 | $18,395 |
| Sumitomo Pharma America, Inc. | 4 | $12,668 |
| Boehringer Ingelheim Canada Ltd.ltee | 14 | $3,520 |
| Genentech, Inc. | 1 | $2,413 |
| Boehringer Ingelheim International GmbH | 3 | $1,344 |
| Boehringer Ingelheim RCV GmbH & Co KG | 1 | $130 |
How this compares
$5,288,507 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lorazepam | 34 | $150 |
| Zolpidem Tartrate | 26 | $135 |
| Citalopram HbrCitalopram Hydrobromide | 13 | $129 |
| Sertraline Hcl | 11 | $16 |
| Trazodone Hcl | 23 | $14 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Long Beach
- Haig GoenjianLong Beach$6.3M
- Christopher ReistLong Beach$2.9M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.